Thema: US61225M1027
GLUE, US61225M1027
entrepreneur-1340649_1920.jpg - Foto: THN
Monte Rosa Therapeutics stock: MRT-8102 shows gout activity in rabbits
Monte Rosa Therapeutics stock is in focus after preclinical MRT-8102 findings in gout. A Phase 2 trial is expected to start this quarter.
ad-hoc-news.de, vor 40 Minuten
GLUE, US61225M1027
UBS upgrades Monte Rosa Therapeutics stock to Hold while ...
GFORCE-1 enrolled 108 subjects and cut hsCRP 85 percent on October 1, 2026. Monte Rosa Therapeutics stock targets Phase 2 in Q4 2026.
ad-hoc-news.de, 16.10.26 01:52 Uhr
GLUE, US61225M1027
UBS raises target for Monte Rosa stock from USD 17 to USD ...
LifeSci kept Buy on Monte Rosa stock on October 3, 2026. Second-quarter revenue was USD 8.97 million and GAAP net loss USD 43.40 million.
ad-hoc-news.de, 14.10.26 02:54 Uhr
GLUE, US61225M1027
HC Wainwright sets USD 25 target for Monte Rosa stock
For Monte Rosa stock, GFORCE-1 enrolled 108 subjects and cut hsCRP 85 percent. Gout testing is expected in Q4 2026 or Q1 2027, with initial data in H2 2027.
ad-hoc-news.de, 05.10.26 06:07 Uhr
GLUE, US61225M1027
Monte Rosa Therapeutics stock fell 6.75 percent after Phase ...
